keyword
MENU ▼
Read by QxMD icon Read
search

falcon trial

keyword
https://www.readbyqxmd.com/read/29783894/fulvestrant-in-management-of-hormone-receptor-positive-metastatic-breast-cancer
#1
Maryam Nemati Shafaee, Matthew James Ellis
Fulvestrant is a steroidal selective estrogen receptor degrader that was approved by the US FDA in 2002 for treatment of ER-positive metastatic breast cancer (ER + MBC) post-progression on aromatase inhibitors. In 2016, the label was updated to include endocrine therapy naive ER + MBC. While initially fulvestrant was thought to be equivalent to aromatase inhibitors with monthly dose of 250 mg intramuscular injection, several postmarketing trials challenged this understanding. Subsequently, the recommended dose changed to 500 mg monthly plus loading dose, and this was proven to be superior to anastrozole in efficacy...
May 22, 2018: Future Oncology
https://www.readbyqxmd.com/read/29782510/individual-differences-in-learning-correlate-with-modulation-of-brain-activity-induced-by-transcranial-direct-current-stimulation
#2
Brian Falcone, Atsushi Wada, Raja Parasuraman, Daniel E Callan
Transcranial direct current stimulation (tDCS) has been shown to enhance cognitive performance on a variety of tasks. It is hypothesized that tDCS enhances performance by affecting task related cortical excitability changes in networks underlying or connected to the site of stimulation facilitating long term potentiation. However, many recent studies have called into question the reliability and efficacy of tDCS to induce modulatory changes in brain activity. In this study, our goal is to investigate the individual differences in tDCS induced modulatory effects on brain activity related to the degree of enhancement in performance, providing insight into this lack of reliability...
2018: PloS One
https://www.readbyqxmd.com/read/29769167/impact-of-sex-on-comparative-outcomes-of-bivalirudin-versus-unfractionated-heparin-in-patients-with-acute-coronary-syndromes-undergoing-invasive-management-a-pre-specified-analysis-of-the-matrix-trial
#3
Giuseppe Gargiulo, Bruno R da Costa, Enrico Frigoli, Cataldo Palmieri, Marco Stefano Nazzaro, Camillo Falcone, Armando Liso, Carlo Vigna, Fabio Abate, Marco Comeglio, Roberto Diletti, Gabriele Gabrielli, Emilio Di Lorenzo, Pietro Mazzarotto, Marco Zimarino, Claudio Moretti, Antonio Colombo, Carlo Penzo, Giampaolo Pasquetto, Salvatore Brugaletta, Fabio Ferrari, Gavino Casu, Vincenzo Guiducci, Antonio Dellavalle, Francesco Liistro, Ciro Mauro, Arnoud W J Van't Hof, Elmir Omerovic, Salvatore Curello, Jose Maria de la Torre Hernandez, Stefano De Servi, Flavia Belloni, Stephan Windecker, Marco Valgimigli
AIMS: To assess whether bivalirudin compared with unfractionated heparin (UFH) is associated with consistent outcomes in male and female patients with acute coronary syndrome (ACS) undergoing invasive management. METHODS AND RESULTS: In the MATRIX program,7213 patients were randomized to bivalirudin or UFH.Patients in bivalirudin group were subsequently assigned to receive or not to receive a post-PCI infusion.The 30-day coprimary outcomes were major adverse cardiovascular and cerebrovascular events (MACE),defined as death,myocardial infarction,or stroke,and net adverse clinical events (NACE),defined as MACE or major bleeding...
May 15, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29622449/one-year-clinical-outcome-of-biodegradable-polymer-sirolimus-eluting-stent-in-all-comers-population-insight-from-the-ulisse-registry-ultimaster-italian-multicenter-all-comers-stent-registry
#4
Cosmo Godino, Alessandro Beneduce, Giuseppe Ferrante, Alfonso Ielasi, Andrea Carlo Pivato, Mauro Chiarito, Alberto Cappelletti, Giulia Perfetti, Valeria Magni, Eugenio Prati, Stefania Falcone, Adele Pierri, Stefano De Martini, Matteo Montorfano, Rosario Parisi, David Rutigliano, Nicola Locuratolo, Angelo Anzuini, Maurizio Tespilli, Alberto Margonato, Alberto Benassi, Carlo Briguori, Franco Fabbiocchi, Bernhard Reimers, Antonio Bartorelli, Antonio Colombo
BACKGROUND: This study was designed to confirm in a large population of unselected patients the promising results of Ultimaster® biodegradable polymer sirolimus-eluting stent (BP-SES) already shown in previous trial. METHODS: ULISSE is an observational, multicenter, national registry evaluating all patients undergoing PCI with the Ultimaster® BP-SES. Incidence of 1-year TLF (cardiac death or target vessel MI or clinically indicated TLR) was the primary endpoint...
June 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29619024/extracellular-ngfr-spacers-allow-efficient-tracking-and-enrichment-of-fully-functional-car-t-cells-co-expressing-a-suicide-gene
#5
Monica Casucci, Laura Falcone, Barbara Camisa, Margherita Norelli, Simona Porcellini, Anna Stornaiuolo, Fabio Ciceri, Catia Traversari, Claudio Bordignon, Chiara Bonini, Attilio Bondanza
Chimeric antigen receptor (CAR)-T cell immunotherapy is at the forefront of innovative cancer therapeutics. However, lack of standardization of cellular products within the same clinical trial and lack of harmonization between different trials have hindered the clear identification of efficacy and safety determinants that should be unveiled in order to advance the field. With the aim of facilitating the isolation and in vivo tracking of CAR-T cells, we here propose the inclusion within the CAR molecule of a novel extracellular spacer based on the low-affinity nerve-growth-factor receptor (NGFR)...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29574365/health-related-quality-of-life-from-the-falcon-phase-iii-randomised-trial-of-fulvestrant-500-mg-versus-anastrozole-for-hormone-receptor-positive-advanced-breast-cancer
#6
John F R Robertson, Kwok-Leung Cheung, Shinzaburo Noguchi, Zhimin Shao, Arnold Degboe, Jasmine Lichfield, Jackie Thirlwell, Mehdi Fazal, Matthew J Ellis
BACKGROUND: The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (LA/MBC). Furthermore, overall health-related quality of life (HRQoL) was maintained and comparable for fulvestrant and anastrozole. Here, we present additional analyses of patient-reported HRQoL outcomes from FALCON...
May 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29559142/first-detection-of-cryptosporidium-parvum-in-falcons-falconiformes-diagnosis-molecular-sequencing-therapeutic-trial-and-epidemiological-assessment-of-a-possible-emerging-disease-in-captive-falcons
#7
Panagiotis Azmanis, Antonio di Somma, Lucia Pappalardo, Christu-Das Silvanose, Berit Bangoura
Cryptosporidiosis in raptors and falcons is well-known to be caused by Cryptosporidium baileyi and associated mainly with respiratory pathology. This report presents the diagnosis of an atypical cryptosporidiosis event caused by Cryptosporidium parvum, that to the authors' knowledge, is a case observed for the first time in falcons. Two falcons (Gyrfalcon x Peregrine hybrids) were presented for annual check without any clinical signs. Hematology, biochemistry, fecal and crop parasitology, radiographic and endoscopic examinations were performed...
March 15, 2018: Veterinary Parasitology
https://www.readbyqxmd.com/read/29531324/differential-histopathologic-parameters-in-colorectal-cancer-liver-metastases-resected-after-triplets-plus-bevacizumab-or-cetuximab-a-pooled-analysis-of-five-prospective-trials
#8
Chiara Cremolini, Massimo Milione, Federica Marmorino, Federica Morano, Gemma Zucchelli, Alessia Mennitto, Michele Prisciandaro, Sara Lonardi, Alessio Pellegrinelli, Daniele Rossini, Francesca Bergamo, Giuseppe Aprile, Lucio Urbani, Luca Morelli, Marta Schirripa, Giovanni Gerardo Cardellino, Matteo Fassan, Gabriella Fontanini, Filippo de Braud, Vincenzo Mazzaferro, Alfredo Falcone, Filippo Pietrantonio
BACKGROUND: Many factors, including histopathologic parameters, seem to influence the prognosis of patients undergoing resection of colorectal cancer liver metastases (CRCLM), although their relative weight is unclear. Histopathologic growth patterns (HGPs) of CRCLM may affect sensitivity to antiangiogenics. We aimed at evaluating differences in histopathologic parameters of response according to the use of bevacizumab or cetuximab as first-line targeted agents, and at exploring the prognostic and predictive role of HGPs...
April 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29487697/-dpyd-and-ugt1a1-genotyping-to-predict-adverse-events-during-first-line-folfiri-or-folfoxiri-plus-bevacizumab-in-metastatic-colorectal-cancer
#9
Chiara Cremolini, Marzia Del Re, Carlotta Antoniotti, Sara Lonardi, Francesca Bergamo, Fotios Loupakis, Beatrice Borelli, Federica Marmorino, Valentina Citi, Enrico Cortesi, Roberto Moretto, Monica Ronzoni, Gianluca Tomasello, Alberto Zaniboni, Patrizia Racca, Angela Buonadonna, Giacomo Allegrini, Vincenzo Ricci, Samantha Di Donato, Vittorina Zagonel, Luca Boni, Alfredo Falcone, Romano Danesi
Our study addresses the issue of the clinical reliability of three candidate DPYD and one UGT single nucleotide polymorphisms in predicting 5-fluorouracil- and irinotecan-related adverse events. To this purpose, we took advantage of a large cohort of metastatic colorectal cancer patients treated with first-line 5-fluorouracil- and irinotecan-based chemotherapy regimens (i.e., FOLFIRI or FOLFOXIRI) plus bevacizumab in the randomized clinical trial TRIBE by GONO (clinicaltrials.gov: NCT00719797), in which adverse events were carefully and prospectively collected at each treatment cycle...
January 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29470701/preservation-of-gonadal-function-in-women-undergoing-chemotherapy-a-systematic-review-and-meta-analysis-of-the-potential-role-for-gonadotropin-releasing-hormone-agonists
#10
REVIEW
Lisa C Hickman, Natalia C Llarena, Lindsey N Valentine, Xiaobo Liu, Tommaso Falcone
PURPOSE: To evaluate the available randomized controlled trials (RCTs) in the literature investigating the use of gonadotropin-releasing hormone agonist (GnRHa) co-treatment for ovarian preservation in women receiving chemotherapy. METHODS: A systematic review of the literature was performed from 1960 through 2017 to identify relevant RCTs. Included patients had lymphoma, ovarian cancer, or breast cancer. The primary outcome was the proportion of women who retained ovarian function after chemotherapy...
April 2018: Journal of Assisted Reproduction and Genetics
https://www.readbyqxmd.com/read/29468029/patterns-of-activity-and-body-temperature-of-aldabra-giant-tortoises-in-relation-to-environmental-temperature
#11
Wilfredo Falcón, Rich P Baxter, Samuel Furrer, Martin Bauert, Jean-Michel Hatt, Gabriela Schaepman-Strub, Arpat Ozgul, Nancy Bunbury, Marcus Clauss, Dennis M Hansen
We studied the temperature relations of wild and zoo Aldabra giant tortoises ( Aldabrachelys gigantea ) focusing on (1) the relationship between environmental temperature and tortoise activity patterns ( n  = 8 wild individuals) and (2) on tortoise body temperature fluctuations, including how their core and external body temperatures vary in relation to different environmental temperature ranges (seasons; n  = 4 wild and n  = 5 zoo individuals). In addition, we surveyed the literature to review the effect of body mass on core body temperature range in relation to environmental temperature in the Testudinidae...
February 2018: Ecology and Evolution
https://www.readbyqxmd.com/read/29450827/progression-free-survival-results-in-postmenopausal-asian-women-subgroup-analysis-from-a-phase-iii-randomized-trial-of-fulvestrant-500-mg-vs-anastrozole-1-mg-for-hormone-receptor-positive-advanced-breast-cancer-falcon
#12
Shinzaburo Noguchi, Matthew J Ellis, John F R Robertson, Jackie Thirlwell, Mehdi Fazal, Zhimin Shao
BACKGROUND: The international, phase III FALCON study (NCT01602380) in postmenopausal patients with hormone receptor-positive, locally advanced/metastatic breast cancer (LA/MBC) who had not received prior endocrine therapy, demonstrated statistically significant improvement in progression-free survival (PFS) for patients who received fulvestrant 500 mg vs anastrozole 1 mg. This subgroup analysis evaluated PFS in Asian (randomized in China, Japan, or Taiwan) and non-Asian patients from the FALCON study...
May 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29450468/activity-and-safety-of-cetuximab-plus-modified-folfoxiri-followed-by-maintenance-with-cetuximab-or-bevacizumab-for-ras-and-braf-wild-type-metastatic-colorectal-cancer-a-randomized-phase-2-clinical-trial
#13
Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi, Giuseppe Aprile, Francesca Bergamo, Gianluca Masi, Roberta Grande, Giuseppe Tonini, Claudia Mescoli, Giovanni Gerardo Cardellino, Luigi Coltelli, Lisa Salvatore, Domenico Cristiano Corsi, Cristiana Lupi, Donatello Gemma, Monica Ronzoni, Emanuela Dell'Aquila, Federica Marmorino, Francesca Di Fabio, Maria Laura Mancini, Lorenzo Marcucci, Gabriella Fontanini, Vittorina Zagonel, Luca Boni, Alfredo Falcone
Importance: The combination of a triple-drug chemotherapy regimen with an anti-epidermal growth factor receptor (EGFR) agent as a first-line treatment of metastatic colorectal cancer (mCRC) showed promising activity along with safety concerns in single-arm phase 2 trials. The role of maintenance following chemotherapy and anti-EGFR and the optimal regimen to be adopted are not established. Objectives: To evaluate the activity and safety of cetuximab plus modified FOLFOXIRI (mFOLFOXIRI) and explore the role of maintenance with cetuximab or bevacizumab in RAS and BRAF wild-type mCRC...
April 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29440218/impact-of-renin-angiotensin-system-inhibitors-on-clinical-outcomes-and-ventricular-remodelling-after-transcatheter-aortic-valve-implantation-rationale-and-design-of-the-rastavi-randomised-multicentre-study
#14
Ignacio J Amat-Santos, Pablo Catalá, Felipe Diez Del Hoyo, Jose A Fernandez-Diaz, Juan H Alonso-Briales, María Del Trigo, Ander Regueiro, Pablo Juan-Salvadores, Vicenç Serra, Enrique Gutierrez-Ibanes, Antonio J Muñoz-García, Luis Nombela-Franco, Manel Sabate, Victor A Jimenez-Diaz, Bruno García Del Blanco, Javier López, Luis H Varela-Falcón, Teresa Sevilla, Roman Arnold, Ana Revilla, J Alberto San Roman
INTRODUCTION: Transcatheter aortic valve implantation (TAVI) as a treatment in severe aortic stenosis (AS) is an excellent alternative to conventional surgical replacement. However, long-term outcomes are not benign. Renin-angiotensin system (RAS) blockade has shown benefit in terms of adverse remodelling in severe AS and after surgical replacement. METHODS AND ANALYSIS: The RAS blockade after TAVI (RASTAVI) trial aims to detect if there is a benefit in clinical outcomes and ventricular remodelling with this therapeutic strategy following the TAVI procedure...
February 13, 2018: BMJ Open
https://www.readbyqxmd.com/read/29353165/prognostic-value-of-primary-tumour-resection-in-synchronous-metastatic-colorectal-cancer-individual-patient-data-analysis-of-first-line-randomised-trials-from-the-arcad-database
#15
K L van Rooijen, Q Shi, K K H Goey, J Meyers, V Heinemann, E Diaz-Rubio, E Aranda, A Falcone, E Green, A de Gramont, D J Sargent, C J A Punt, M Koopman
Indication for primary tumour resection (PTR) in asymptomatic metastatic colorectal cancer (mCRC) patients is unclear. Previous retrospective analyses suggest a survival benefit for patients who underwent PTR. The aim was to evaluate the prognostic value of PTR in patients with synchronous mCRC by analysis of recent large RCTs including systemic therapy with modern targeted agents. Individual patient data (IPD) of 3423 patients enrolled into 8 randomised controlled trials (RCTs) with first-line systemic therapy in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analysed...
March 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29346320/c-phycocyanin-and-phycocyanobilin-as-remyelination-therapies-for-enhancing-recovery-in-multiple-sclerosis-and-ischemic-stroke-a-preclinical-perspective
#16
REVIEW
Giselle Pentón-Rol, Javier Marín-Prida, Viviana Falcón-Cama
Myelin loss has a crucial impact on behavior disabilities associated to Multiple Sclerosis (MS) and Ischemic Stroke (IS). Although several MS therapies are approved, none of them promote remyelination in patients, limiting their ability for chronic recovery. With no available therapeutic options, enhanced demyelination in stroke survivors is correlated with a poorer behavioral recovery. Here, we show the experimental findings of our group and others supporting the remyelinating effects of C-Phycocyanin (C-PC), the main biliprotein of Spirulina platensis and its linked tetrapyrrole Phycocyanobilin (PCB), in models of these illnesses...
January 18, 2018: Behavioral Sciences
https://www.readbyqxmd.com/read/29324972/prognostic-and-predictive-role-of-neutrophil-lymphocytes-ratio-in-metastatic-colorectal-cancer-a-retrospective-analysis-of-the-tribe-study-by-gono
#17
E Dell'Aquila, C Cremolini, T Zeppola, S Lonardi, F Bergamo, G Masi, M Stellato, F Marmorino, M Schirripa, F Urbano, M Ronzoni, G Tomasello, A Zaniboni, P Racca, A Buonadonna, G Allegrini, E Fea, S Di Donato, S Chiara, G Tonini, D Tomcikova, L Boni, A Falcone, D Santini
Background: Neutrophil/Lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial. Patients and Methods: Pts enrolled in TRIBE trial were included...
January 8, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29215098/proxies-of-quality-of-life-in-metastatic-colorectal-cancer-analyses-in-the-recourse-trial
#18
COMMENT
Eric Van Cutsem, Alfredo Falcone, Rocio Garcia-Carbonero, Yoshito Komatsu, Alessandro Pastorino, Marc Peeters, Yasuhiro Shimada, Kentaro Yamazaki, Takayuki Yoshino, Alberto Zaniboni, Nadia Amellal, Akira Kanehisa, Robert Winkler, Lukas Makris, Robert J Mayer, Atsushi Ohtsu, Josep Tabernero
Background: In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). There was no formal analysis of quality of life (QoL) in RECOURSE. The aim of the present analysis was to assess proxies of QoL during the RECOURSE treatment period, in terms of adverse events (AEs) likely to affect QoL and Eastern Cooperative Oncology Group performance status (ECOG PS)...
2017: ESMO Open
https://www.readbyqxmd.com/read/29209533/vinorelbine-in-braf-v600e-mutated-metastatic-colorectal-cancer-a-prospective-multicentre-phase-ii-clinical-study
#19
Chiara Cremolini, Filippo Pietrantonio, Gianluca Tomasello, Vincenzo Dadduzio, Roberto Moretto, Federica Morano, Marta Schirripa, Carlotta Antoniotti, Giovanni Fucà, Francesca Bergamo, Daniele Rossini, Federico Nichetti, Stamatia Ziampiri, Michele Ghidini, Federica Marmorino, Michele Prisciandaro, Alfredo Falcone, Filippo De Braud, Fotios Loupakis, Sara Lonardi
Background: BRAF V600E mutation defines a specific colorectal cancer (CRC) subgroup with poor prognosis. Promising preclinical data showed synthetically lethal activity of mitotic spindle poisons on BRAF- mutated and BRAF -like CRC models. We designed a phase II trial to test the activity of vinorelbine in patients with BRAF V600E mutated metastatic CRC (mCRC). Patients and methods: Patients progressed to or not deemed eligible for standard treatments received oral (60 mg/sqm) or intravenous (25 mg/sqm) vinorelbine, on days 1 and 8 every 21 days...
2017: ESMO Open
https://www.readbyqxmd.com/read/29208668/a-polymorphism-within-the-vitamin-d-transporter-gene-predicts-outcome-in-metastatic-colorectal-cancer-patients-treated-with-folfiri-bevacizumab-or-folfiri-cetuximab
#20
Martin D Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Dongyun Yang, Yu Sunakawa, Satoshi Matsusaka, Yan Ning, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Diana L Hanna, Shivani Soni, Alberto Puccini, Wu Zhang, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Heinz-Josef Lenz
Purpose: Vitamin D exerts its inhibitory influence on colon cancer growth by inhibiting Wnt signaling and angiogenesis. We hypothesized that SNPs in genes involved in vitamin D transport, metabolism, and signaling are associated with outcome in metastatic colorectal cancer (mCRC) patients treated with first-line FOLFIRI and bevacizumab. Experimental Design: 522 mCRC patients enrolled in the FIRE-3 (discovery cohort) and TRIBE (validation set) trials treated with FOLFIRI/bevacizumab were included in this study...
February 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
120390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"